CoChat

Restoration of the Majority of the Visual Spectrum by Using Modified Volvox Channelrhodopsin-1

Open access
Tomita, Hiroshi, Sugano, Eriko, Murayama, Namie, Ozaki, Taku, Nishiyama, Fumiaki, Tabata, Kitako, Takahashi, Maki, Saito, Takehiko, Tamai, Makoto · 2014 · Molecular Therapy
Cited by 73

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

We previously showed that blind rats whose vision was restored by gene transfer of Chlamydomonas channelrhodopsin-2 (ChR2) could only detect wavelengths less than 540 nm because of the action spectrum of the transgene product. Volvox-derived channelrhodopsin-1, VChR1, has a broader spectrum than ChR2. However, the VChR1 protein was mainly localized in the cytoplasm and showed weak ion channel properties when the VChR1 gene was transfected into HEK293 cells. We generated modified Volvox channelrhodopsin-1 (mVChR1), which is a chimera of Volvox channelrhodopsin-1 and Chlamydomonas channelrhodopsin-1 and demonstrated increased plasma membrane integration and dramatic improvement in its channel properties. Under whole-cell patch clamp, mVChR1-expressing cells showed a photo-induced current upon stimulation at 468-640 nm. The evoked currents in mVChR1-expressing cells were ~30 times larger than those in VChR1-expressing cells. Genetically, blind rats expressing mVChR1 via an adeno-associated virus vector regained their visual responses to light with wavelengths between 468 and 640 nm and their recovered visual responses were maintained for a year. Thus, mVChR1 is a candidate gene for gene therapy for restoring vision, and gene delivery of mVChR1 may provide blind patients access to the majority of the visible light spectrum.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2014.81

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 73

Metadata

Authors
Tomita, H., Sugano, E., Murayama, N., Ozaki, T., Nishiyama, F., Tabata, K., Takahashi, M., Saito, T., & Tamai, M.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2014-08
Volume
22
Issue
8
Pages
1434-1440
ISSN
1525-0016 (ISSN-L)
OpenAlex
W1989252491
Cited by
73
References
2
FWCI
2.28
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Restoration of the Majority of the Visual Spectrum by Using Modified Volvox Channelrhodopsin-1. https://app.cochat.ai/papers/10.1038/mt.2014.81
The paper
Tomita, H., Sugano, E., Murayama, N., Ozaki, T., Nishiyama, F., Tabata, K., Takahashi, M., Saito, T., & Tamai, M. (2014). Restoration of the Majority of the Visual Spectrum by Using Modified Volvox Channelrhodopsin-1. Molecular Therapy. https://doi.org/10.1038/mt.2014.81

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.